Newly finalized guidance from the US Food and Drug Administration lays out how the agency assesses user fees for combination products, as well as how sponsors can qualify for waivers and other programs that may reduce cost.
“Application User Fees for Combination Products Guidance for Industry and FDA Staff,” which replaces a 2005 guidance document of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?